Alnylam director sells shares after option exercise
ALNYLAM PHARMACEUTICALS, INC. director David E I Pyott exercised a stock option for 3,830 shares of common stock at a conversion price of $70.20 per share and sold the same 3,830 shares in open-market transactions on June 1, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ALNYLAM PHARMACEUTICALS, INC. director David E I Pyott exercised a stock option for 3,830 shares of common stock at a conversion price of $70.20 per share and sold the same 3,830 shares in open-market transactions on June 1, 2026. The reported sales occurred at weighted average prices around $297.71–$302.65 per share under a pre-arranged Rule 10b5-1(c) trading plan, and the options were due to expire on June 3, 2026. Following these transactions, he holds 1,582 shares of common stock directly and 27,900 shares indirectly through the David E I Pyott Trust, of which he is trustee.
Insider Trade Summary 10b5-1
Exercise and Sale: 3,830 shares ($877K approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
PYOTT DAVID E I
Role
Director
Sold
3,830 shs ($1.15M)
Approx. gross sale proceeds
$1.15M
Approx. exercise cost
$269K
Approx. pre-tax spread
$877K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,830 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,830 | $0.00 | $0.00 |
| Sale | Common Stock | 921 | $297.71 | $274K |
| Sale | Common Stock | 1,175 | $298.91 | $351K |
| Sale | Common Stock | 1,222 | $299.87 | $366K |
| Sale | Common Stock | 495 | $300.72 | $149K |
| Sale | Common Stock | 17 | $302.65 | $5K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 contracts (Direct);
Common Stock — 1,582 shares (Direct);
Common Stock — 27,900 shares (Indirect, by Trust)
Footnotes (7)
- F1. The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.
- F2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6. The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee.
- F7. This stock option was fully vested and exercisable as of June 3, 2017.
Key Figures
Options exercised: 3,830 shares
Exercise price: $70.20/share
Shares sold: 3,830 shares
+5 more
8 metrics
Options exercised
3,830 shares
Stock option for common stock exercised on June 1, 2026
Exercise price
$70.20/share
Conversion or exercise price of stock option exercised
Shares sold
3,830 shares
Total common shares sold in open-market transactions
Sale price range
$297.31–$302.65
Weighted average sale prices across multiple transactions
Direct holdings after
1,582 shares
Common stock directly owned after transactions
Trust holdings
27,900 shares
Common stock held by the David E I Pyott Trust
Option expiration
June 3, 2026
Expiration date of the exercised stock option
Option fully vested
June 3, 2017
Date option became fully vested and exercisable
Key Terms
Rule 10b5-1(c) trading plan, weighted average sales price, Stock Option (Right to Buy), fully vested and exercisable, +2 more
6 terms
Rule 10b5-1(c) trading plan financial
"The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person"
A Rule 10b5-1(c) trading plan is a legally defined, pre-set schedule that lets company insiders automatically buy or sell stock at specified times or under set formulas when they are not in possession of undisclosed, sensitive information. Think of it like an automatic payment plan for trades: because the instructions are written in advance, trades under the plan help protect insiders from allegations of trading on secret information and give investors clearer expectations about when insiders will transact, which can affect liquidity and perceived transparency.
weighted average sales price financial
"The price reported represents the weighted average sales price of shares sold in multiple transactions"
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
fully vested and exercisable financial
"This stock option was fully vested and exercisable as of June 3, 2017"
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did ALNY director David E I Pyott report?
David E I Pyott reported exercising options for 3,830 Alnylam common shares and selling the same 3,830 shares in open-market transactions on June 1, 2026. The filing shows both the derivative option exercise and subsequent common stock sales.
What stock option did David E I Pyott exercise in this ALNY Form 4?
He exercised a stock option for 3,830 Alnylam common shares with a conversion or exercise price of $70.20 per share. The option was fully vested and exercisable since June 3, 2017 and was scheduled to expire on June 3, 2026, according to the filing.
Was the ALNY insider sale by David E I Pyott under a Rule 10b5-1 plan?
Yes. The filing states all reported transactions were made under a Rule 10b5-1(c) trading plan adopted on November 12, 2025. Such plans pre-schedule trades, which can make the timing less indicative of the insider’s view of the stock.
Did David E I Pyott retain any ALNY stock options after this exercise?
The Form 4 shows a derivative transaction in which a 3,830-share stock option was exercised, leaving zero shares remaining under that option. The derivative summary section is otherwise empty, indicating no additional derivative positions are reported in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates